



DISCLOSURES AND RESOLUTION OF CONFLICT OF INTEREST

The following faculty members have indicated that they do not have any relevant financial relationships with ineligible companies* to disclose. **Indicates that this individual's presentations will include discussion of off-label or unapproved usage.

Rohan Garje, M.D.,
Julie Gralow, M.D.

Jonathan C. Trent, M.D.

The following faculty members have indicated that they have relevant financial relationships with ineligible companies* to disclose. **Indicates that this individual's presentations will include discussion of off-label or unapproved usage.

Neeraj Agarwal, M.D., is a researcher for Arnivas, Astellas, AstraZeneca, Bavarian Nordic, Bristol-Myers Squibb, Calithera, Celldex, Clovis, Crispr, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, GlaxoSmithKline, Immunomedics, Janssen, Lava, Medivation, Merck, Nektar, Neoleukin, New Link Genetics, Novartis, Oric, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda and Tracoon. He is a consultant for Merck, Aveo, Exelixis, Eli Lilly and Foundation Medicine.

Charu Aggarwal, M.D., is a consultant with Genentech, Eli Lilly, Celgene, Merck, AstraZeneca, Blueprint Genetics, Shionogi, Daiichi Sankyo, Regeneron, Sanofi, Eisai, BeiGene, Turning Point, Pfizer, Janssen and Boehringer Ingelheim. She is also a researcher with Genentech/Roche, Incyte, MacroGenics, Merck Sharp & Dohme and AstraZeneca/MedImmune.

Manmeet Ahluwalia, M.D., faculty and director for this activity, is a researcher for AstraZeneca, Bayer, Bristol-Myers Squibb, Incyte, Merck, Mimivax, Novocure and Pharmacocyclics. He is a consultant for Apollomics, Bayer, Caris Life Sciences, Celularity, GSK, Insightec, Janssen, Kiyatec, Novocure, Prelude, Pyramid Biosciences, SDP Oncology, Tocagen, ViewRay, Voyager Therapeutics, Xofigo, Varian Medical System and CAIRIN Therapeutics. He has individual stocks/stock options with Cytodyn, Doctible, Medinnovate Advisors and Mimivax.

Tanios Bekaii-Saab, M.D., has received research funding from Agios, Arys, Arcus, Atreca, Boston Biomedical, Bayer, Eisai, Celgene, Eli Lilly, Ipsen, Clovis, Seattle Genetics, Genentech, Novartis, Mirati, Merus, Abgenomics, Incyte, Pfizer and BMS. He is a consultant with Stemline, AbbVie, Boehringer Ingelheim, Janssen, Daiichi Sankyo, Natera, TreosBio, Celularity, Caladrius Biosciences, Exact Science, Sobi, BeiGene, Kanaph, AstraZeneca, Deciphera, MJH Life Sciences, Aptitude Health, Illumina and Foundation Medicine, IDMC/DSMB: Fibrogen, Suzhou Kintor, AstraZeneca, Exelixis, Merck/Eisai, PanCan and 1Globe. He is on the scientific advisory board with Imugene, Immuneering, Xilis, Replimune, Artiva and Sun Biopharma. He received royalties from Uptodate and has invention/patents with WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene and WO/2019/055687: METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.

Jenny Chang, M.D., is an adviser with AstraZeneca, Eli Lilly and Merck.

John Diaz, M.D., is a researcher with Merck and Astra/Zeneca, a consultant with Dysis, an adviser with Seagen and a member of the speakers' bureau for AstraZeneca.

Luis Diaz, M.D., is an adviser with PetDx, Merck, Delfi Diagnostics, Innovatus CP, Se'er, Kinnate, Neophore, Thrive Detect (acquired by Exact) and Personal Genome Diagnostics (acquired by LabCorp). He has royalties related to genomic and ctDNA analyses, next-generation sequencing and immunotherapy for mismatch repair deficiency. He has an executive role with Epitope and Jounce Therapeutics. He has ownership in Epitope, Jounce Therapeutics, PetDx, Se'er, Delfi, Kinnate and Neophore. His spouse receives equity with Amgen.

Pauline Funchain, M.D., is a researcher for Pfizer, BMS and Taiho Oncology. She is a consultant with Novartis, Eisai, BMS and Merck and an adviser for GigaGen and Nirvana Healthcare Ventures.

Petros Grivas, M.D., is a consultant for AstraZeneca, Astellas Pharma, Boston Gene, Bristol-Myers Squibb, Dyania Health, EMD Serono, Exelixis, Fresenius Kabi, Genentech/Roche, Gilead Sciences, GlaxoSmithKline, Guardant Health, G1 Therapeutics, Infinity Pharmaceuticals, Janssen, Lucence Health, MSD, Mirati Therapeutics, Pfizer, PureTech, QED Therapeutics, Regeneron Pharmaceuticals, Seattle Genetics, Silverback Therapeutics, 4D Pharma PLC and UroGen. His institution has received grants from Bavarian Nordic, Bristol-Myers Squibb, Clovis Oncology, Debiopharm, EMD Serono, G1 Therapeutics, Gilead Sciences, GlaxoSmithKline, MSD, Mirati Therapeutics, Pfizer and QED Therapeutics.

Thomas Herzog, M.D., is an adviser with AstraZeneca, Caris, Clovis, Eisai, Epsilon, Genentech, GSK, Johnson & Johnson, Merck and Seagen. He receives royalties from UpToDate and has an executive role with GOG Foundation.

Nagla Karim, M.D. is a researcher with Exelixis, BMS and Pfizer. She is a consultant with Amgen and Jazz. She is an advisor with Jazz and BMS. She is on the speakers' bureau with Regeneron.

Reshma Mahtani, D.O. is a consultant for Agendia, Daiichi, Eisai, Genentech, Hologic, Gilead, Lilly, Merck, Novartis, Pfizer, Puma, Seagen, Sermonix and Stemline.

Roisin O'Cearbhaill, M.D. is a researcher for Bayer/Celgene/Juno, Tesaro/GSK, Merck, Ludwig Cancer Institute, AbbVie/StemCentrx, Regeneron, TCR2 Therapeutics, Atara Biotherapeutics, Marker Therapeutics, Syndax Pharmaceuticals, Genmab/Seagen Therapeutics, Sellas Therapeutics, Genentech, Kite Pharma and Gynecologic Oncology Foundation. She is on the non-compensated steering committee for the PRIMA, Moonstone (Tesaro/GSK) and DUO-O (AstraZeneca) studies and non-compensated adviser for Carina Biotech. She is on the advisory board for GSK, Regeneron, R-PHARM, Bayer, Seattle Genetics, Fresenius Kabi, Gynecologic Oncology Foundation and Immunogen. She is on the speakers' bureau with Curio, MJH/PER, OncLive, GOG Foundation, SITC, Once off research presentation GSK. Other disclosures include travel to attend meetings of Hitech Health and the Irish Society of Medical Oncology. She is also assistant editor for JAMA Network Open.

Sumanta K. Pal, M.D., has received travel assistance from CRISPR and IPSON.

Luis E. Raez, M.D., is a researcher with BMS, Genentech, Merck, Velos, Lilly Oncology, Loxo, Nanthealth, Bio Pharma, Guardant Health, Natera, Syndax and AstraZeneca.

Neeta Somaiah, M.D., is a researcher with AstraZeneca, Advenchen, Innovent, Cogent and Ascentage. He is also an adviser for Aadi Bioscience, Boehringer Ingelheim and Life Raft Group.

Vivek Subbiah, M.D., is a researcher with AbbVie, Agensys, Alfasigma, Altum, Amgen, Bayer, Berg Health, Blueprint Medicines Corporation, Boston Biomedical, Boston Pharmaceuticals, Celgene Corporation, D3 Bio, Dragonfly Therapeutics, Exelixis, Fujifilm, GlaxoSmithKline, Idera Pharmaceuticals, Incyte Corporation, Inhibrx, Loxo Oncology, MedImmune, MultiVir, NanoCarrier, National Comprehensive Cancer Network, NCI-CTEP, Northwest Biotherapeutics, Novartis, PharmaMar, Pfizer, Relay Therapeutics, Roche/Genentech, Takeda, Turning Point Therapeutics, MD Anderson Cancer Center and Vegenic. He is a consultant with Helsinn Healthcare, Jazz Pharmaceuticals, Incyte, Loxo Oncology/Eli Lilly, MedImmune, Novartis, QED Therapeutics, Relay Therapeutics, Daiichi Sankyo and R-Pharm US, and has received an honorarium from Medscape.

Tiffany Traina, M.D., is a researcher with Eisai, Pfizer, Novartis, Innocrin Pharma, AstraZeneca, Astellas Pharma, Immunomedics, Genentech/Roche, Daiichi Sankyo, Carrick Pharm and Ayala Pharmaceuticals. She is a consultant for Genentech/Roche, Pfizer, AstraZeneca, Merck, Daiichi Sankyo, Eisai, Exact Sciences, Foundation Medicine, Ayala Pharmaceuticals, Gilead Sciences, Blueprint Medicines, Ellipses Pharma, Fuji Pharma, ITeos Therapeutics, Agendia, Novartis, GlaxoSmithKline, GE Healthcare, Biotheranostics, Infinity Pharmaceuticals and Seattle Genetics.

Everett Vokes, M.D., is a consultant with BMS and EMD Serono. He doesn't receive payment from either company. He has individual stocks/stock options with McKesson and Coordination Pharmaceuticals.

Patrick Wen, M.D., is a researcher for AstraZeneca/Medimmune, BeiGene, Celgene, Chimerix, Eli Lilly, Genentech/Roche, Kazia, MediciNova, Merck, Novartis, Nuvation Bio, Puma, Servier, Vascular Biogenics and VBI Vaccines. He is an adviser for AstraZeneca, Bayer, Black Diamond, Boehringer Ingelheim, Boston Pharmaceuticals, Celularity, Chimerix, Day One Bio, Genenta, GlaxoSmithKline, Karyopharm, Merck, Mundipharma, Novartis, Novocure, Nuvation Bio, Prelude Therapeutics, Sapience, Servier, Sagimet, Vascular Biogenics, and VBI Vaccines.

All of the relevant financial relationships listed for these individuals have been mitigated.

Other individuals involved in planning, content review, approval or moderating for this educational activity have no relevant financial relationships to disclose with ineligible companies*.

**Ineligible companies are those whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.*